Dr David Munn reviews the latest understanding in cancer immunotherapy, focusing on new pathways to target and novel combination therapies.
This activity is intended for hematology/oncology specialists, dermatologists, pulmonologists, and other healthcare professionals who treat patients with cancer immunotherapies.
The goal of this activity is to review the rationale for new immunotherapy approaches to reactivating immune surveillance in patients with cancer.
Approximate Time to Complete: 1.25 hrs
Credit Available: Feb. 28, 2019 - Feb. 28, 2020
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 1.25
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 1.25